Phase 2 N=35 Maximal Suppression of the Androgen Axis in Clinically Localized Prostate Cancer
Cancer · Prostate Neoplasms
Primary: Prostate Tissue DHT — 0.03; 0.06; 0.03 ng/g
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=72 GM-CSF, Sargramostim in Women With Recurrent Ovarian Cancer
Ovarian Cancer · Fallopian Tube Cancer
Primary: Median Time to Treatment Termination (TTT) — 78 days
Phase 2 N=14 Umbilical Cord Blood Transplantation In Patients With Hematologic Malignancies Using A Myeloablative Preparative Regimen
Hematologic Malignancies · Disorder Related to Transplantation · Hematopoietic Malignancy
Primary: Event Free Survival (EFS) for Research Participants — 4 Participants
Phase 2 N=191 Clinical Study to Investigate Safety and Efficacy of GSK933776 in Adult Patients With Geographic Atrophy Secondary to Age-related Macular Degeneration
Atrophy, Geographic
Primary: Change From Baseline in the Area of Geographic Atrophy (GA) Assessed by Color Fundus Photographs (FP) in the Study Eye — -0.52; -0.94; -0.99; -0.96 square millimeter (m^2)
Phase 2 N=94 Safety and Efficacy Study of Topical Cantharidin for the Treatment of Molluscum Contagiosum
Molluscum Contagiosum
Primary: Number of Subjects Who Achieve Complete Clearance at 6 Weeks — 10; 7; 2; 3 Participants
Phase 2 N=87 Vinorelbine Tartrate and Cyclophosphamide in Combination With Bevacizumab or Temsirolimus in Treating Patients With Recurrent or Refractory Rhabdomyosarcoma
Adult Rhabdomyosarcoma · Childhood Alveolar Rhabdomyosarcoma · Childhood Pleomorphic Rhabdomyosarcoma
Primary: Event Free Survival Probability — 0.23; 0.43 Probability — p=0.0124
Phase 2 N=135 A Clinical Trial To Evaluate PF-05089771 On Its Own And As An Add-On Therapy To Pregabalin (Lyrica) For The Treatment Of Pain Due To Diabetic Peripheral Neuropathy (DPN)
Diabetic Neuropathy, Painful
Primary: Daily Pain Numeric Rating Scale (NRS) — 6.17; 6.62; 6.35; 5.45 Unit on a scale
Phase 2 N=16 Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination Administered in Patients Infected With Chronic Genotype 1 or 4 HCV for Use in the Peri-Operative Liver Transplantation Setting
Hepatitis C Virus Infection
Primary: Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12) — 87.5 percentage of participants
Phase 2 N=41 S1014 Abiraterone Acetate in Treating Patients With Prostate Cancer Who Have Undergone Initial Hormone Therapy
Prostate Cancer
Primary: Number of Patients With Undetectable PSA — 5 Participants
Phase 2 N=16 Double-blind Pilot Trial of Mirtazapine for the Treatment of Co-occurring AD/MDD.
Major Depressive Disorder · Alcohol Use Disorder
Primary: Drinks Per Drinking Day — 3.5; 4.4 Drinks per drinking day
Phase 2 N=18 Cell Therapy for Craniofacial Bone Defects
Cleft Palate · Trauma
Primary: Bone Regeneration — 1.5; 3.3 implant sites
Phase 2 N=50 Psychopharmacology for Cocaine Dependence - Buspirone
Cocaine Dependence
Primary: Attentional Bias as Assessed by Score on the Stroop Task — -13.90333; 27.118; -9.361269; 15.35407 milliseconds
Phase 2 N=1,379 GR270773 In The Treatment Of Suspected Or Confirmed Gram-Negative Severe Sepsis In Adults
Sepsis
Primary: Percentage of Participants With 28-Day All Cause Mortality — 26.9; 25.8; 31.3 Percentage of participants — p=0.329
Phase 2 N=36 Pentostatin and Lymphocyte Infusion in Preventing Graft Rejection in Patients Who Have Undergone Donor Stem Cell Transplant
Acute Lymphoblastic Leukemia · Acute Myeloid Leukemia · Chronic Lymphocytic Leukemia
Primary: Percentage Patients With an Increase of at Least 10 Percentage Points in Donor T-cell Chimerism — 60; 30; 33.3 percentage of participants
Phase 2 N=36 Peanut Reactivity Reduced by Oral Tolerance in an Anti-IgE Clinical Trial
Peanut Allergy · Food Allergy
Primary: Tolerance of 2000 mg 6 Weeks After Last Dose of Omalizumab/Placebo — 23; 1 Participants